Samsungbioepis Co,.Ltd
Samsung Bioepis Co., Ltd., a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative approach in the biosimilars industry. Founded in 2012, the company has rapidly established itself as a key player in the global market, focusing on the development and commercialisation of high-quality biosimilars and biologics. With a strong presence in major operational regions including North America, Europe, and Asia, Samsung Bioepis offers a diverse portfolio of products that includes biosimilars for oncology and autoimmune diseases. Their commitment to rigorous research and development, combined with advanced manufacturing capabilities, sets them apart in a competitive landscape. Notable achievements include strategic partnerships with global pharmaceutical leaders, enhancing their market position and expanding access to affordable treatments. Samsung Bioepis continues to drive innovation, making significant contributions to the healthcare sector.
DitchCarbon Score
How does Samsungbioepis Co,.Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsungbioepis Co,.Ltd's score of 39 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsungbioepis Co,.Ltd's reported carbon emissions
In 2024, Samsungbioepis Co., Ltd. reported total carbon emissions of approximately 6,323,850 kg CO2e. This figure includes Scope 1 emissions of about 1,220,325 kg CO2e and Scope 2 emissions of approximately 5,103,525 kg CO2e. Notably, the company also disclosed Scope 3 emissions, which totalled around 37,809,000 kg CO2e from purchased goods and services, alongside significant contributions from other categories such as business travel and employee commute. Comparatively, in 2023, the total emissions were about 6,295,405 kg CO2e, with Scope 1 at approximately 1,209,479 kg CO2e and Scope 2 at around 5,085,926 kg CO2e. This indicates a slight increase in emissions year-on-year. Samsungbioepis has set ambitious climate commitments, aiming to reduce GHG emissions by 32% from a 2022 baseline by the year 2030. This target applies to both Scope 1 and Scope 2 emissions, reflecting a comprehensive approach to mitigating their carbon footprint. The emissions data for Samsungbioepis is cascaded from its parent company, Samsung Biologics Co., Ltd., which plays a significant role in the company's sustainability initiatives. The commitment to reducing emissions aligns with broader industry standards and reflects a proactive stance towards climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,433,412 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,296,110 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsungbioepis Co,.Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
